QQ客服 官方微博 反馈留言

浏览/检索结果: 共1条，第1-1条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review 期刊论文 Drug Design, Development and Therapy, 2015, 卷号: 9, 页码: 5277-5285 作者:  Huang, Ruixue;  Ding, Ping;  Yang, Fei* 收藏  |  浏览/下载：15/0  |  提交时间：2019/12/03 CDH1  as a tumor suppressor gene  contributes sporadic breast cancer (BC) progression. However  the association between CDH1 hypermethylation and BC  and its clinicopathological significance remains unclear. We conducted a meta-analysis to investigate the relationship between the CDH1 methylation profile and the major clinicopathological features. A detailed literature was searched through the electronic databases PubMed  Web of Science™  and EMBASE™ for related research publications. The data were extracted and assessed by two reviewers independently. Odds ratios (ORs) with corresponding confidence intervals (CIs) were calculated and summarized respectively. The frequency of CDH1 methylation was significantly higher in invasive ductal carcinoma than in normal breast tissues (OR =5.83  95% CI 3.76–9.03  P<0.00001). CDH1 hypermethylation was significantly higher in estrogen receptor (ER)-negative BC than in ER-positive BC (OR =0.62  95% CI 0.43–0.87  P=0.007). In addition  we found that the CDH1 was significantly methylated in HER2-negative BC than in HER2-positive BC (OR =0.26  95% CI 0.15–0.44  P<0.00001). However  CDH1 methylation frequency was not associated with progesterone receptor (PR) status  or with grades  stages  or lymph node metastasis of BC patients. Our results indicate that CDH1 hypermethylation is a potential novel drug target for developing personalized therapy. CDH1 hypermethylation is strongly associated with ER-negative and HER2-negative BC  respectively  suggesting CDH1 methylation status could contribute to the development of novel therapeutic approaches for the treatment of ER-negative or HER2-negative BC with aggressive tumor biology.